201 related articles for article (PubMed ID: 30229873)
21. Treatment of metastasized melanoma with combined checkpoint inhibition in a patient with highly active multiple sclerosis.
Hoffmann F; Fröhlich A; Schäfer N; Keil VC; Landsberg J; Herrlinger U; Sirokay J
J Dermatol; 2020 May; 47(5):e184-e185. PubMed ID: 32096240
[No Abstract] [Full Text] [Related]
22. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
23. The impact of the immunotherapy revolution on lymph nodal surgery.
Eggermont AMM
Bull Cancer; 2020 Jun; 107(6):640-641. PubMed ID: 31610910
[No Abstract] [Full Text] [Related]
24. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
25. Successful treatment of cutaneous metastatic melanoma with high-dose intralesional interleukin-2 treatment combined with cryosurgery.
Martinez-Lopez A; Almazan-Fernandez FM; Perez-Lopez I; Aguayo-Carreras P; Salvador-Rodriguez L; Cuenca-Barrales C; Arias-Santiago S
Dermatol Ther; 2018 Jul; 31(4):e12612. PubMed ID: 29766618
[No Abstract] [Full Text] [Related]
26. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
27. [Results of adjuvant therapy with the preparation Poly-a Poly-u in patients with malignant melanoma during a 10-year observation].
Pawlicki M; Jońca M; Krzemieniecki K; Zuchowska-Vogelgesang B
Wiad Lek; 1993 Dec; 46(23-24):912-4. PubMed ID: 7900387
[TBL] [Abstract][Full Text] [Related]
28. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
Alniemi DT; Fischer A; Greene LA; Pierson JC
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives.
Testori AAE; Ribero S; Indini A; Mandalà M
Am J Clin Dermatol; 2019 Dec; 20(6):817-827. PubMed ID: 31177507
[TBL] [Abstract][Full Text] [Related]
30. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
31. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.
Prasanna T; McNeil CM; Nielsen T; Parkin D
Immunotherapy; 2018 Mar; 10(3):171-175. PubMed ID: 29370723
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
33. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
[No Abstract] [Full Text] [Related]
34. Emerging therapies for melanoma.
Katipamula R; Markovic SN
Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
[TBL] [Abstract][Full Text] [Related]
35. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
36. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
Nardin C; Pelletier F; Puzenat E; Aubin F
Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
[No Abstract] [Full Text] [Related]
37. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
[TBL] [Abstract][Full Text] [Related]
38. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.
Acaba-Berrocal LA; Lucio-Alvarez JA; Mashayekhi A; Ho AC; Dunn JP; Shields CL
JAMA Ophthalmol; 2018 Oct; 136(10):1205-1207. PubMed ID: 30054605
[No Abstract] [Full Text] [Related]
39. A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab.
Matsumoto S; Kijima T; Matsuoka Y; Yamamoto M; Fujii Y
Eur J Cancer; 2020 May; 131():104-107. PubMed ID: 32234272
[No Abstract] [Full Text] [Related]
40. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]